Blueprint Medicines (BPMC) Stock Chart - Revenue & Earnings | Quarter Chart

📊 Income Statement

Revenue by Product

Collaboration and LicenseCollaboration revenueRoyaltyProduct
025M50M75M100M125M150M175M200MQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025

Revenue by Geography

UNITED STATESNon-US
025M50M75M100M125M150M175M200MQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025

Revenue, Gross Profit, Operating and Net Income

RevenueGross ProfitOperating IncomeNet Income
050M100M150M200M250M300M350M400MQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025

Margin (%)

Gross MarginOperating MarginNet Income Margin
03875112150188225262300Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025

Operating Expenses

Research And Development ExpensesSelling And Marketing ExpensesGeneral And Administrative ExpensesOther Expenses
038M75M112M150M188M225M262M300MQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025

EBITDA

EBITDA
-50M-19M12M44M75M106M138M169M200MQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025

EPS

EPSEPS Diluted
001222344Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025

Revenue Variation (%)

Revenue Variation
-9-08172634435160Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025

Income Variation (%)

Gross Profit VariationOperating Income VariationNet Income Variation
0815223038455260Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025

Revenue YoY Variation (%)

Revenue YoY Variation
0255075100125150175200Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025

Income YoY Variation (%)

Gross Profit YoY VariationOperating Income YoY VariationNet Income YoY Variation
0255075100125150175200Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025

Price-to-Earning Ratio

P/E Ratio
-404659701K2K2K3K3K4KQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025

Income Breakdown

Rule Of 40 (EBITDA)Rule Of 40 (FCF)
03875112150188225262300Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025

Per Share Metrics

Operating IncomeInterest IncomeTotal Other Income Expenses NetNet Income
050M100M150M200M250M300M350M400MQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025

Expense Ratios

Revenue Per ShareNet Income Per ShareOperating Cash Flow Per Share
001222344Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025
💰 Cash Flow Statement

Operating Cash Flow

Research And Ddevelopement To RevenueCapex To RevenueStock Based Compensation To Revenue
000111222Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025

Free Cash Flow

Cash Flow to Debt Ratio

Cash At End Of Period
025M50M75M100M125M150M175M200MQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025
🏦 Balance Sheet
📈 Key Metrics